Investigating the Link Between Left Ventricular Hypertrophy and Anemia in End-Stage Renal Disease
Exploring Anemia's Impact on LVH in ESRD
DOI:
https://doi.org/10.69750/dmls.01.03.028Keywords:
End-stage renal disease, left ventricular hypertrophy, anemia, hemodialysis, echocardiographyAbstract
Background:ESRD significantly burdens healthcare systems worldwide. Its related complications, such as LVH and anemia, lead to increased morbidity and mortality. Left Ventricular Hypertrophy (LVH), which mirrors an increase in myocardial mass and wall thickness, is easily identified in patients with ESRD. Anemia, a state of low hemoglobin, increases cardiac work
Aims and Objective: To explore anemia and its association with LVH in ESRD patients on maintenance hemodialysis by detailed echocardiographic assessment and comprehensive blood analysis.
Methodology: This comparative study was carried out at a teaching hospital, namely Ghurki Teaching Hospital and a tertiary care hospital, Mayo Hospital, Lahore, Pakistan from March 2023 to April 2024. A purposive sample of 200 adults on maintenance hemodialysis with ESRD was obtained through stratified random sampling techniques and the participants were grouped based on anemia status: anemic; (hemoglobin <13g/dL in males, <12g/dL in females) or non-anemic. The data were analyzed using SPSS software (Version 26) by employing independent t-test to compare the means, chi-squared test for categorical variables, A p-value < 0. 05 was considered significant.
Results:In patients with anemia, the LVMI was significantly (P≤0.05) higher than in patients without anemia. Anemia was found to be a significant (P≤0.05) predictor of an increase in LVMI over time, indicating its role in the development of LVH.
Conclusion:The findings of present research indicated that, as shown by echocardiography, there is a substantial correlation between LVH and anemia in patients on maintenance of hemodialysis.
Downloads
References
Omar T, Çağdaş M, Artaç İ, Karakayalı M, İliş D, Arslan A, et al. The relationship between heart functions and anemia in patients with end-stage renal disease receiving hemodialysis. The European Research Journal. 2024;10(1):118-26.
Ito T, Akamatsu K. Echocardiographic manifestations in end-stage renal disease. Heart Failure Reviews. 2024;29(2):465-78.
TAHARA O, DUTTA P. Left Ventricular Hypertrophy (LVH) in different Stages of Chronic Kidney Disease (CKD) Patients and its Correlation with Anaemia. Journal of Bangladesh College of Physicians & Surgeons. 2024;42(1).
Li H-L, Tai P-H, Hwang Y-T, Lin S-W. A five-year longitudinal study of the relation between end-stage kidney disease as the outcomes. BMC nephrology. 2020;21:1-10.
Nguyen NN, Van Duong P, Ngoc Mai TH, Vo NH, Luong DK, Ngo TH. Left Ventricular Mass Index in End-Stage Renal Disease Patients during Hemodialysis and Continuous Ambulatory Peritoneal Dialysis. International Journal of Clinical Practice. 2023;2023.
Coimbra S, Catarino C, Sameiro Faria M, Nunes JPL, Rocha S, Valente MJ, et al. The Association of Leptin with Left Ventricular Hypertrophy in End-Stage Kidney Disease Patients on Dialysis. Biomedicines. 2023;11(4):1026.
Radhakrishnan A, Pickup LC, Price AM, Law JP, McGee KC, Fabritz L, et al. Coronary microvascular dysfunction is associated with degree of anaemia in end‐stage renal disease. BMC Cardiovascular Disorders. 2021;21(1):211.
Nardi E, Mulè G, Giammanco A, Mattina A, Geraci G, Nardi C, et al. Left ventricular hypertrophy in chronic kidney disease: a diagnostic criteria comparison. Nutrition, Metabolism and Cardiovascular Diseases. 2021;31(1):137-44.
Io H, Muto M, Sasaki Y, Ishizaka M, Kano T, Fukuzaki H, et al. Impact of anemia treatment for left ventricular hypertrophy using long-acting erythropoietin-stimulating agents from the pre-dialysis to maintenance dialysis period in patients with chronic kidney disease, retrospective longitudinal cohort study. BMC nephrology. 2023;24(1):74.
Alansari H, Wald R, Deva DP, Ong J, Chang LD-J, Kiaii M, et al. Relationships between cardiac structural and functional assessment by cardiac MRI and hemoglobin in end-stage renal disease. Journal of Nephrology. 2021;34:1561-3.
Bhagat N, Dawman L, Naganur S, Tiewsoh K, Kumar B, Pratyusha K, et al. Impact of anemia on the cardiovascular status in children with chronic kidney disease: A pilot study. Clinical Nutrition ESPEN. 2022;47:283-7.
Maqbool S, Shafiq S, Ali S, Rehman MEU, Malik J, Lee KY. Left Ventricular Hypertrophy (LVH) and Left Ventricular Geometric Patterns in Patients with Chronic Kidney Disease (CKD) Stage 2-5 With Preserved Ejection Fraction (EF): A Systematic Review to Explore CKD Stage-wise LVH Patterns. Current problems in cardiology. 2023;48(4):101590.
Ali S, Umar RM, Ahmed B, Ali F, Saboor QA, Pannu FY. Effect of Hemodialysis Duration on Left Ventricular Hypertrophy in Patients of Chronic Kidney Disease. Pakistan Journal of Medical & Health Sciences. 2022;16(11):238-.
Badawy A, Nigm DA, Ezzat GM, Gamal Y. Interleukin 18 as a new inflammatory mediator in left ventricular hypertrophy in children with end-stage renal disease. Saudi Journal of Kidney Diseases and Transplantation. 2020;31(6):1206-16.
Shaltout AH, Samir S, Lashin FI, Sherif MH, Aboelnasr MS. Correlation of parathyroid hormone level with left ventricular mass in patients with end-stage kidney disease on hemodialysis. Journal of The Egyptian Society of Nephrology and Transplantation. 2021;21(3):124-9.
Rehman F, Hayat T, Fatima H, Shafiq M, Masood U, Batool R. Integrative Approaches in the Management of Diabetic Foot Ulcers: A Comparative Study of Conventional and Alternative Therapies: Integrative Approaches in Diabetic Foot Ulcer Therapy. DEVELOPMENTAL MEDICO-LIFE-SCIENCES. 2024;1(2):44-52.
Lee M, Lee KJ, Lee YH, Kim D, Shin SJ, Yoon HE. The combined clinical impact of red blood cell distribution width and vascular calcification on cardiovascular events and mortality in patients with end-stage kidney disease. Kidney Research and Clinical Practice. 2022;41(3):351.
Murkamilov I, Sabirov I, Fomin V, Murkamilova ZA, Yusupov F. Interrelation of Changes in the Left Ventricular Myocardium and Evidence of Clinical and Laboratory Indicators in Chronic Kidney Disease of Elderly. Advances in Gerontology. 2022;12(1):72-8.
Raza H, Idrees B, Khan HU, Bakhtiar K, Ahmad S, Shuja A. Evaluating the Impact of Smoking and Hyperlipidemia in Patients with Atherosclerotic Cardiovascular Disease: Smoking and Hyperlipidemia in Atherosclerosis. Pakistan Journal of Health Sciences. 2024:136-40.
Okamura T, Tsukamoto K, Arai H, Fujioka Y, Ishigaki Y, Koba S, et al. Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2022. Journal of Atherosclerosis and Thrombosis. 2024;31(6):641-853.
Hedayatnia M, Asadi Z, Zare-Feyzabadi R, Yaghooti-Khorasani M, Ghazizadeh H, Ghaffarian-Zirak R, et al. Dyslipidemia and cardiovascular disease risk among the MASHAD study population. Lipids in health and disease. 2020;19:1-11.
Damaskos C, Garmpis N, Kollia P, Mitsiopoulos G, Barlampa D, Drosos A, et al. Assessing cardiovascular risk in patients with diabetes: an update. Current cardiology reviews. 2020;16(4):266-74.
Hedegaard BS, Bork CS, Kaltoft M, Klausen IC, Schmidt EB, Kamstrup PR, et al. Equivalent impact of elevated lipoprotein (a) and familial hypercholesterolemia in patients with atherosclerotic cardiovascular disease. Journal of the American College of Cardiology. 2022;80(21):1998-2010.
Mahtta D, Ramsey DJ, Al Rifai M, Nasir K, Samad Z, Aguilar D, et al. Evaluation of aspirin and statin therapy use and adherence in patients with premature atherosclerotic cardiovascular disease. JAMA network open. 2020;3(8):e2011051-e.
Acosta S, Johansson A, Drake I. Diet and lifestyle factors and risk of atherosclerotic cardiovascular disease—a prospective cohort study. Nutrients. 2021;13(11):3822.
Sun T, Chen M, Shen H, PingYin, Fan L, Chen X, et al. Predictive value of LDL/HDL ratio in coronary atherosclerotic heart disease. BMC Cardiovascular Disorders. 2022;22(1):273.
Németh Á, Daróczy B, Juhász L, Fülöp P, Harangi M, Paragh G. Assessment of associations between serum lipoprotein (a) levels and atherosclerotic vascular diseases in hungarian patients with familial hypercholesterolemia using data mining and machine learning. Frontiers in Genetics. 2022;13:849197.
Vassy JL, Lu B, Ho Y-L, Galloway A, Raghavan S, Honerlaw J, et al. Estimation of atherosclerotic cardiovascular disease risk among patients in the veterans affairs health care system. JAMA Network Open. 2020;3(7):e208236-e.
Jarab AS, Alefishat EA, Al‐Qerem W, Mukattash TL, Al‐Hajjeh DaM. Lipid control and its associated factors among patients with dyslipidaemia in Jordan. International Journal of Clinical Practice. 2021;75(5):e14000.
Downloads
PlumX Metrics
Published
Issue
Section
License
Copyright (c) 2024 DEVELOPMENTAL MEDICO-LIFE-SCIENCES
This work is licensed under a Creative Commons Attribution 4.0 International License.
The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/public domain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
